Heidi Wang

Company: OBI Pharma

Job title: Chief Executive Officer

Seminars:

Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBI™ Platform 3:30 pm

Advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumour proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations Challenges and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting Benefits of GlycOBI™ Platform: Producing homogenous ADCs…Read more

day: Conference Day 1